Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637895 · ClinicalTrials.gov registry record · Phase 4
Vortioxetine for Posttraumatic Stress Disorder
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT02637895 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 41 participants.
The verdict
NCT02637895, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
Post-traumatic stress disorder (PTSD) can result from having experienced or witnessed a traumatic event. Patients with PTSD symptoms can sometimes experience symptom relief after treatment with antidepressants; however, few patients experience complete symptom relief. There is a need to develop new treatments for PTSD. This study will evaluate if 12 weeks of using Vortioxetine relieves PTSD symptoms. Vortioxetine has been approved for the treatment of depression; however, Vortioxetine has not been approved by the Food and Drug Administration for the treatment of PTSD.
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-02-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02637895
The ClinicalTrials.gov registry entry for NCT02637895 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02637895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02637895 about?
NCT02637895 is a clinical study titled "Vortioxetine for Posttraumatic Stress Disorder". Post-traumatic stress disorder (PTSD) can result from having experienced or witnessed a traumatic event. Patients with PTSD symptoms can sometimes experience symptom relief after treatment with antidepressants; however, few patients experience complete symptom relief. There is a need to develop new ...
What is the current status of trial NCT02637895?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2016-12. Estimated completion is 2020-02-06.
What interventions are being tested in trial NCT02637895?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02637895?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.